Kristie L. Kahl | Authors


Post Hoc Analysis Suggests Lenvatinib Therapy May Continue in Patients with Unresectable HCC, Child–Pugh class Liver Function

July 01, 2021

Patients with unresectable hepatocellular carcinoma with Child-Pugh class B liver function experienced a similar tumor size reduction as their Child-Pugh class A counterparts, all treated with lenvatinib, according to a post-hoc analysis of the phase 3 REFLECT study.

Cilta-Cel Shows High Response Rate Even After Longer Follow-Up in R/R Multiple Myeloma

June 16, 2021

Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.